Marleen Kok, MD, PhD, on Preoperative Nivolumab for Triple-Negative Breast Cancer: Initial Results From the BELLINI Trial

Posted: Monday, October 3, 2022

Marleen Kok, MD, PhD, of The Netherlands Cancer Institute in Amsterdam, discusses the clinical implications of her findings on the use of short-term preoperative nivolumab, either as monotherapy or in combination with low-dose doxorubicin or novel immunotherapy combinations, to induce immune activation in patients with early-stage triple-negative breast cancer with tumor-infiltrating lymphocytes.